A new dual-action molecule developed by Roche Holding appeared to show greater potency than single-hormone drugs in regulating metabolism in obese patients with type 2 diabetes, according to a study in Science Translational Medicine. The drug mimics the effects of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide and may also be administered to patients at a lower dosage, reducing the risk of side effects such as nausea and vomiting.

Full Story:

Related Summaries